Prevention and Quality of Life of Lung Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 1383

Special Issue Editor


E-Mail Website
Guest Editor
Department of Thoracic Surgery, West German Cancer Center, Medical Faculty, University Hospital Essen, Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany
Interests: thoracic surgery; lung cancer; pleural immothelioma; lung metastases; mediastinal tumors

Special Issue Information

Dear Colleagues,

We are excited to announce a Special Issue focused on the "Prevention and Quality of Life of Lung Cancer". As professionals dedicated to enhancing the well-being and health outcomes of our patients, we recognize the pivotal role of prevention strategies and the profound impact of interventions that seek to improve the quality of life of individuals diagnosed with lung cancer.

This Special Issue aims to encompass a broad spectrum of topics related to the prevention of lung cancer and improving the quality of life of those affected by it. We welcome original research, review articles, clinical trials, and perspectives on topics including, but not limited to, the following:

- Novel preventive strategies and early detection techniques.

- Behavioral interventions, including smoking cessation and lifestyle modifications.

- The psychosocial dynamics of living with lung cancer.

- Palliative care approaches for advanced-stage lung cancer.

- The role of rehabilitation and exercise in enhancing quality of life.

- Patient-reported outcomes and their implications for care.

By sharing your insights, research, and experiences, you will be contributing to a comprehensive resource that aims to inform and shape best practices, inspire future research, and, most importantly, bring about meaningful change in the lives of patients. Your work will reach a vast audience of peers, healthcare professionals, researchers, and policymakers, amplifying its impact.

We urge you to seize this opportunity to showcase your expertise and contribute to a topic of profound importance. Together, let us advance the discourse on lung cancer prevention and enhance the quality of life of those affected by this formidable disease.

We are looking forward to your valuable contributions!

Prof. Dr. Servet Bölükbas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thoracic surgery
  • lung cancer
  • Quality of life
  • Prevention
  • PROMs
  • rehabilitation
  • prehabilitation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1796 KiB  
Article
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
by Fabian Doerr, Tobias Leschczyk, Konstantinos Grapatsas, Hruy Menghesha, Natalie Baldes, Georg Schlachtenberger, Matthias B. Heldwein, Maximilian Michel, Alexander Quaas, Lars Hagmeyer, Katja Höpker, Thorsten Wahlers, Kaid Darwiche, Christian Taube, Martin Schuler, Khosro Hekmat and Servet Bölükbas
Cancers 2024, 16(2), 465; https://doi.org/10.3390/cancers16020465 - 22 Jan 2024
Cited by 1 | Viewed by 1069
Abstract
Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term [...] Read more.
Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total n = 90) were selected by pair matching. Group A (n = 60) had no postoperative tobacco smoking. Group B (n = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (p = 0.82); 64% and 62%, respectively, were male (p = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; p = 0.87). All relevant baseline characteristics we collected were similar (p > 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (p = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; p <0.001) and QOL (vitality (VT): +10 vs. −10, p = 0.017; physical role function (RP): +8 vs. −17, p = 0.012; general health perceptions (GH): +12 vs. −5, p = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, p = 0.034; 3-year OS rate: 96.2% vs. 81.0%, p = 0.02; 5-year OS rate: 80.0% vs. 64.0%, p = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. Full article
(This article belongs to the Special Issue Prevention and Quality of Life of Lung Cancer)
Show Figures

Figure 1

Back to TopTop